Rein Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNTX research report →
About the company
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide.
- CEO
- James Brian Windsor
- IPO
- 2017
- Employees
- 11
- HQ
- Austin, TX, US
Price Chart
- Market Cap
- $27.72M
- P/E
- -0.52
- P/S
- 0.00
- P/B
- 2.60
- EV/EBITDA
- -1.31
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -258.45%
- ROIC
- -120.92%
- Revenue
- $0 · 0.00%
- Net Income
- $-49,871,000 · 20.69%
- EPS
- $-1.96 · 44.16%
- Op Income
- $-21,931,000
- FCF YoY
- 13.14%
- 52W High
- $2.18
- 52W Low
- $0.86
- 50D MA
- $1.10
- 200D MA
- $1.27
- Beta
- 1.35
- Avg Volume
- 789.60K
Get TickerSpark's AI analysis on RNTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 27, 26 | VON RICKENBACH JOSEF H | buy | 4,500 |
| May 26, 26 | VON RICKENBACH JOSEF H | buy | 23,190 |
| May 22, 26 | VON RICKENBACH JOSEF H | buy | 15,950 |
| May 21, 26 | VON RICKENBACH JOSEF H | buy | 3,420 |
| May 8, 26 | WINDSOR JAMES BRIAN | other | 150,000 |
| Apr 30, 26 | WINDSOR JAMES BRIAN | buy | 25,000 |
| Nov 14, 25 | Voss Capital, LP | buy | 104,183 |
| Oct 27, 25 | Voss Capital, LP | buy | 92,642 |
| Oct 24, 25 | Voss Capital, LP | buy | 30,176 |
| Oct 28, 25 | Voss Capital, LP | buy | 178,392 |
Our RNTX coverage
Recent articles, reports, and earnings notes.
No research on RNTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RNTX report →Similar companies
Peers in the same neighborhood.